BACKGROUND: Long-term survivors of Wilms tumor and neuroblastoma may experience significant late adverse effects from their disease and its therapy. Little is known, however, about the health-related quality of life experienced by these survivors. PROCEDURE: Health-related quality of life, measured by the 36-Item Short Form Health Survey (SF-36), was assessed from self-report in adult survivors of Wilms tumor (N = 654) and neuroblastoma (N = 432) who participated in the Childhood Cancer Survivor Study. RESULTS: More than 90% of the study population was 18-34 years old at interview, and 58% were females. There was no significant difference on any SF-36 subscale or summary scale between the two diagnostic groups. On average, survivors reported no decrement on the Physical Component Summary scale of the SF-36 when compared to population norms. However, both groups scored significantly below the population mean score (50) on the Mental Component Summary Scale of the SF-36 (Wilms tumor mean = 41.66, standard error = 2.19, P < 0.0001; neuroblastoma mean = 42.41, standard error = 2.23, P < 0.0001) reflecting decreased emotional health. Independent risk factors for lower scores on this scale included female gender, Native American race, unemployment, and household income below $20,000. CONCLUSIONS: Adult survivors of childhood Wilms tumor and neuroblastoma do not differ from population norms on most health-related quality of life (HRQL) measures. These data, however, indicate that the emotional well being of adult survivors may be compromised. Health care providers should be aware of the risk of adverse outcomes in emotional health even many years after treatment and cure. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: Long-term survivors of Wilms tumor and neuroblastoma may experience significant late adverse effects from their disease and its therapy. Little is known, however, about the health-related quality of life experienced by these survivors. PROCEDURE: Health-related quality of life, measured by the 36-Item Short Form Health Survey (SF-36), was assessed from self-report in adult survivors of Wilms tumor (N = 654) and neuroblastoma (N = 432) who participated in the Childhood Cancer Survivor Study. RESULTS: More than 90% of the study population was 18-34 years old at interview, and 58% were females. There was no significant difference on any SF-36 subscale or summary scale between the two diagnostic groups. On average, survivors reported no decrement on the Physical Component Summary scale of the SF-36 when compared to population norms. However, both groups scored significantly below the population mean score (50) on the Mental Component Summary Scale of the SF-36 (Wilms tumor mean = 41.66, standard error = 2.19, P < 0.0001; neuroblastoma mean = 42.41, standard error = 2.23, P < 0.0001) reflecting decreased emotional health. Independent risk factors for lower scores on this scale included female gender, Native American race, unemployment, and household income below $20,000. CONCLUSIONS: Adult survivors of childhood Wilms tumor and neuroblastoma do not differ from population norms on most health-related quality of life (HRQL) measures. These data, however, indicate that the emotional well being of adult survivors may be compromised. Health care providers should be aware of the risk of adverse outcomes in emotional health even many years after treatment and cure. (c) 2007 Wiley-Liss, Inc.
Authors: Lonnie K Zeltzer; Christopher Recklitis; David Buchbinder; Bradley Zebrack; Jacqueline Casillas; Jennie C I Tsao; Qian Lu; Kevin Krull Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Kirsten K Ness; Melissa M Hudson; Jill P Ginsberg; Rajaram Nagarajan; Sue C Kaste; Neyssa Marina; John Whitton; Leslie L Robison; James G Gurney Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Ann C Mertens; Sarah Brand; Kirsten K Ness; Zhenghong Li; Pauline A Mitby; Anne Riley; Andrea Farkas Patenaude; Lonnie Zeltzer Journal: Psychooncology Date: 2013-10-04 Impact factor: 3.894
Authors: Daniel J Zheng; Kevin R Krull; Yan Chen; Lisa Diller; Yutaka Yasui; Wendy Leisenring; Pim Brouwers; Rebecca Howell; Jin-Shei Lai; Lyn Balsamo; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Nina S Kadan-Lottick Journal: Cancer Date: 2018-06-11 Impact factor: 6.860
Authors: Carmen L Wilson; Tara M Brinkman; Cathleen Cook; Sujuan Huang; Geehong Hyun; Daniel M Green; Wayne L Furman; Nickhill Bhakta; Matthew J Ehrhardt; Matthew J Krasin; Leslie L Robison; Kirsten K Ness; Melissa M Hudson Journal: Cancer Date: 2020-01-10 Impact factor: 6.860
Authors: S Cristina Oancea; Tara M Brinkman; Kirsten K Ness; Kevin R Krull; Webb A Smith; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: J Cancer Surviv Date: 2014-01-24 Impact factor: 4.442
Authors: L Wengenroth; M E Gianinazzi; C S Rueegg; S Lüer; E Bergstraesser; C E Kuehni; G Michel Journal: Qual Life Res Date: 2015-03-18 Impact factor: 4.147
Authors: Inga M R Jóhannsdóttir; Marianne J Hjermstad; Torbjørn Moum; Finn Wesenberg; Lars Hjorth; Henrik Schrøder; Päivi Lähteenmäki; Gudmundur Jónmundsson; Jon H Loge Journal: J Cancer Surviv Date: 2010-01-16 Impact factor: 4.442
Authors: Cheryl L Cox; Deborah A Sherrill-Mittleman; Barth B Riley; Melissa M Hudson; Lauren J Williams; Wendy M Leisenring; Margie G Zacher; Les L Robison Journal: J Cancer Surviv Date: 2012-12-05 Impact factor: 4.442